Search our Database of Scientific Publications and Authors

I’m looking for a

    3829 results match your criteria Thyroid Ophthalmopathy

    1 OF 77

    Serum CYR61 Is Associated with Disease Activity in Graves' Orbitopathy.
    Ocul Immunol Inflamm 2017 May 26:1-7. Epub 2017 May 26.
    a Institute of Vision Research, Department of Ophthalmology , Yonsei University College of Medicine , Seoul , South Korea.
    Purpose: To investigate the clinical implications of cysteine-rich angiogenic inducer 61 (CYR61) in Graves' orbitopathy (GO).

    Methods: Sera from 52 GO patients, 23 Graves' disease (GD) patients, and 20 healthy controls, and orbital fat tissue samples from 12 of 52 GO patients and 8 control subjects were included for analysis. Concentrations of CYR61 were measured from sera with an enzyme-linked immunosorbent assay, and CYR61 mRNA expression levels were evaluated from orbital fat tissue with polymerase chain reaction. Read More

    Changes in Choroidal Perfusion after Orbital Decompression Surgery for Graves' Ophthalmopathy.
    J Ophthalmic Vis Res 2017 Apr-Jun;12(2):183-186
    Private Practice, Retina Group of Washington, Chevy Chase, Maryland, USA.
    Purpose: To assess choroidal perfusion before and after orbital decompression surgery in patients with Graves' ophthalmopathy.

    Methods: In this interventional case series, surgical decompression for optic nerve compromise was performed on four eyes of three patients with Graves' disease. Complete ophthalmic examination including visual acuity, color vision, and intraocular pressure assessment were done pre- and postoperatively. Read More

    [Calculation of orbital fat volumes for determining treatment timing for thyroid- associated ophthalmopathy].
    Nan Fang Yi Ke Da Xue Xue Bao 2017 May;37(5):640-645
    Department of Endocrinology, Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China.E-mail:
    Objective: To analyze the relationship between orbital fat volume and the progression and prognosis of thyroid- associated ophthalmopathy (TAO) and determine the optimal treatment timing for TAO.

    Methods: The clinical data were collected from 35 patients (70 orbits) with a definite diagnosis of TAO between January, 2016 and December, 2016. The correlation between orbital fat volume and the clinical parameters was evaluated. Read More

    Retina and Nerve Fiber Layer Thickness in Eyes with Thyroid-Associated Ophthalmopathy.
    Isr Med Assoc J 2017 May;19(5):277-281
    Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
    Background: Thyroid-associated ophthalmopathy (TAO) is an inflammatory disease that affects the thyroid gland and the eye orbit. Of patients with TAO, 3%-5% have severe sight-threatening disease due to optic neuropathy Optical coherence tomography (OCT), the non-invasive imaging technology that yields high-resolution cross-sectional images of the retina, provides qualitative and quantitative data on the retina.

    Objectives: To apply this technique to quantitatively assess retinal nerve fiber layer (RNFL) and macular ring thicknesses in healthy subjects and in patients with TAO to determine their relationship to the severity of the orbital disease. Read More

    A case-control study of selenoprotein genes polymorphisms and autoimmune thyroid diseases in a Chinese population.
    BMC Med Genet 2017 May 12;18(1):54. Epub 2017 May 12.
    Department of Endocrinology, Jinshan Hospital of Fudan University, No. 1508 Longhang Road, Shanghai, 201508, People's Republic of China.
    Background: Selenium is an essential trace and there is a high selenium concentration in the thyroid gland. Selenium deficiency may impair the thyroid function. The aim of this study was to investigate the association between three selenoprotein genes polymorphisms and autoimmune thyroid diseases. Read More

    Orbital T-Cell Lymphoma with Discrete Enlargements of All Extraocular Muscles Bilaterally in Patient with Moon Face Countenance.
    Case Rep Ophthalmol Med 2017 9;2017:8902162. Epub 2017 Apr 9.
    Department of Pathology, Gifu Municipal Hospital, Gifu, Japan.
    Purpose. To report our findings in a case of orbital T-cell lymphoma in which all of the extraocular muscles (EOMs) were bilaterally and discretely enlarged and the patient had a moon face countenance. Case. Read More

    Decreased microRNA-146a in CD4+T cells promote ocular inflammation in thyroid-associated ophthalmopathy by targeting NUMB.
    Eur Rev Med Pharmacol Sci 2017 Apr;21(8):1803-1809
    Department of Ophthalmology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
    Objective: The aim of the study was to explore the functional role of miR-146a in CD4+T cells of active thyroid-associated ophthalmopathy (TAO) patients and to identify the possible molecular mechanism for the modulation of miR-146a in TAO.

    Patients And Methods: The experimental group collected six cases of peripheral venous blood of patients with active TAO. The healthy control group collected six cases of normal peripheral venous blood. Read More

    Pingmu Decoction Induces Orbital Preadipocytes Apoptosis In Vitro.
    Evid Based Complement Alternat Med 2017 18;2017:2109249. Epub 2017 Apr 18.
    Department of Pharmacy, Long Hua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, South Wan Ping Road No. 725, Shanghai 200032, China.
    Pingmu Decoction is the Traditional Chinese Medicine which has treated Graves' Ophthalmopathy (GO) in the inactive stage for more than ten years. This study was to explore the mechanism of Pingmu Decoction of inhibiting preadipocytes in GO patients from differentiating into mature adipocytes. Human orbital preadipocytes were isolated and cultured through tissue explant method. Read More

    Structural-Functional Features of the Thyrotropin Receptor: A Class A G-Protein-Coupled Receptor at Work.
    Front Endocrinol (Lausanne) 2017 24;8:86. Epub 2017 Apr 24.
    Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany.
    The thyroid-stimulating hormone receptor (TSHR) is a member of the glycoprotein hormone receptors, a sub-group of class A G-protein-coupled receptors (GPCRs). TSHR and its endogenous ligand thyrotropin (TSH) are of essential importance for growth and function of the thyroid gland and proper function of the TSH/TSHR system is pivotal for production and release of thyroid hormones. This receptor is also important with respect to pathophysiology, such as autoimmune (including ophthalmopathy) or non-autoimmune thyroid dysfunctions and cancer development. Read More

    Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases.
    PLoS One 2017 4;12(5):e0176064. Epub 2017 May 4.
    Zhongshan Ophthalmic Center, State Key laboratory of Ophthalmology, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.
    Thyroid associated ophthalmopathy (TAO) is an autoimmune inflammatory disorder which disfigures appearance, threatens vision, and results in a pronounced loss of quality of life. The diversity and ethnic difference of the disease manifestations have made it difficult to tailor therapies for each patient. Few studies have analyzed its characteristics in Chinese populations. Read More

    MicroRNA-146a contributes to CD4(+) T lymphocyte differentiation in patients with thyroid ophthalmopathy.
    Am J Transl Res 2017 15;9(4):1801-1809. Epub 2017 Apr 15.
    Department of Ophthalmology, Shenzhou Eye HospitalLuoyang 471000, Henan, China.
    MicroRNA-146a (miR-146a) is associated with human inflammatory disease, such as thyroid-associated ophthalmopathy (TAO), but its role in human T cells and relevance to TAO remains ambiguous. In this study, T cells of TAO patients showed downregulated expression of miR-146a. We characterized miR-146a in T cells and examined miR-146a as a critical inhibitor of Th1 differentiation processes. Read More

    Teprotumumab for Thyroid-Associated Ophthalmopathy.
    N Engl J Med 2017 05;376(18):1748-1761
    From the Department of Ophthalmology and Visual Sciences, Kellogg Eye Center (T.J.S., R.S.D.), and the Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine (T.J.S.), University of Michigan Medical School, Ann Arbor; the Department of Medicine, Johannes Gutenberg University Medical Center, Mainz, Germany (G.J.K.); Moorfields Eye Hospital, London (D.G.E.); the University of Tennessee Health Science Center, Memphis (J.C.F.); the Oculofacial Plastic Surgery Division, Oregon Health and Science University, Portland (R.A.D.); Eye Wellness Center, Neuro-Ophthalmology of Texas, Houston (R.A.T.); the Department of Ophthalmology, Medical College of Wisconsin, Milwaukee (G.J.H.); the Department of Clinical and Experimental Medicine, University of Pisa, Pisa (A.A.), and the Endocrinology and Diabetology Unit, Fondazione IRCCS Ca' Granda, University of Milan, Milan (M.S.) - both in Italy; the Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles (R.A.G.); the University of Nebraska Medical Center, Omaha (J.W.G.); Barnes-Jewish Hospital, Washington University, St. Louis (S.M.C.); the Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City (E.M.S.); the Department of Ophthalmology, Emory University, Atlanta (B.R.H.); the Department of Ophthalmology, University of Colorado, Aurora (E.M.H.); and River Vision Development, New York (R.M.W., K.G., G.M.).
    Background: Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy. Read More

    Postoperative Outcomes in Graves' Disease Patients: Results from the Nationwide Inpatient Sample Database.
    Thyroid 2017 May 22. Epub 2017 May 22.
    1 Division of Endocrine Surgery, DeWitt Daughtry Family Department of Surgery, University of Miami Leonard M. Miller School of Medicine , Miami, Florida.
    Background: Current surgical indications for Graves' disease include intractability to medical and/or radioablative therapy, compressive symptoms, and worsening ophthalmopathy. Total thyroidectomy for Graves' disease may be technically challenging and lead to untoward perioperative outcomes. This study examines outcomes in patients with Graves' disease who underwent total thyroidectomy and assesses its safety for this patient population. Read More

    Long-term outcomes of orbital fat decompression in Graves' orbitopathy.
    Br J Ophthalmol 2017 Apr 27. Epub 2017 Apr 27.
    Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
    Purpose: To evaluate the long-term clinical efficacy of orbital fat decompression in treating proptosis in Graves' ophthalmopathy (GO).

    Methods: Retrospective review of 1604 eyes of 845 patients with symmetric (1518 eyes) and asymmetric (86 eyes) proptosis who received orbital fat decompression between 2003 and 2014. Changes in Hertel values were evaluated at baseline, 6 months postoperatively and yearly thereafter. Read More

    Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.
    Orphanet J Rare Dis 2017 Apr 20;12(1):72. Epub 2017 Apr 20.
    Academic Medical Center, 22660 1100 DD, Amsterdam, Netherlands.
    Background: Graves' orbitopathy (GO) is an autoimmune condition, which is associated with poor clinical outcomes including impaired quality of life and socio-economic status. Current evidence suggests that the incidence of GO in Europe may be declining, however data on the prevalence of this disease are sparse. Several clinical variants of GO exist, including euthyroid GO, recently listed as a rare disease in Europe (ORPHA466682). Read More

    Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
    PLoS One 2017 18;12(4):e0175274. Epub 2017 Apr 18.
    Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
    Background: Graves' orbitopathy (GO) is an autoimmune inflammatory ocular complication and one of the most frequent manifestations of Graves' disease (GD). Clinical judgment of GO is subjective sometimes leading to clinical and therapeutic challenges. Better tools to diagnose this severe complication are warranted. Read More

    Thyroid-associated Ophthalmopathy.
    Turk J Ophthalmol 2017 Apr 1;47(2):94-105. Epub 2017 Apr 1.
    Ankara University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey.
    Thyroid-associated ophthalmopathy is the most frequent extrathyroidal involvement of Graves' disease but it sometimes occurs in euthyroid or hypothyroid patients. Thyroid-associated ophthalmopathy is an autoimmune disorder, but its pathogenesis is not completely understood. Autoimmunity against putative antigens shared by the thyroid and the orbit plays a role in the pathogenesis of disease. Read More

    (99)Tc(m)-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy.
    Eye (Lond) 2017 May 7;31(5):668-676. Epub 2017 Apr 7.
    The Key Laboratory of National Ministry of Health for Forensic Science, College of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
    PurposeAs an autoimmune inflammatory disorder, active thyroid-associated ophthalmopathy (TAO) is managed optimally by immunosuppression. In this study, we aimed to evaluate octreotide scintigraphy and the level of serum extraocular muscle antibodies in TAO activity.Patients and methodsThis prospective study comprised 304 patients with active TAO (the clinical activity score; CAS≥3), 73 with inactive TAO (CAS<3), 128 with Graves' disease (GD) without ophthalmopathy, and 100 healthy subjects. Read More

    Environmental Issues in Thyroid Diseases.
    Front Endocrinol (Lausanne) 2017 20;8:50. Epub 2017 Mar 20.
    Department of Clinical and Experimental Medicine, University of Messina School of Medicine, Messina, Italy; Master Program of Childhood, Adolescence and Women's Endocrine Health, University of Messina School of Medicine, Messina, Italy; Interdepartmental Program of Molecular & Clinical Endocrinology, and Women's Endocrine Health, University Hospital, Policlinico G. Martino, Messina, Italy.
    Environmental factors are determinant for the appearance of autoimmune thyroid diseases (AITD) in susceptible subjects. Increased iodine intake, selenium, and vitamin D deficiency, exposure to radiation, from nuclear fallout or due to medical radiation, are environmental factors increasing AITD. Cigarette smoking is associated with Graves' disease and Graves' ophthalmopathy, while it decreases the risk of hypothyroidism and thyroid autoimmunity. Read More

    Graves' Ophthalmopathy in a Paediatric Population.
    Klin Monbl Augenheilkd 2017 Apr 22;234(4):591-594. Epub 2017 Mar 22.
    Oculoplastic surgery unit, Jules Gonin Eye Hospital, University of Lausanne, Switzerland.
    Background Graves' disease is an autoimmune disorder leading to hyperthyroidism. It is often associated with ophthalmic manifestations. Graves' disease is reported to be rare in the paediatric population. Read More

    Simultaneous induction of Graves' hyperthyroidism and Graves' ophthalmopathy by TSHR genetic immunization in BALB/c mice.
    PLoS One 2017 20;12(3):e0174260. Epub 2017 Mar 20.
    Department of Endocrinology, Jingling Hospital, Medical School of Nanjing University, Nanjing, P.R. China.
    Background: Graves' disease is the most common form of autoimmune thyroid disorder, characterized by hyperthyroidism due to circulating autoantibodies. To address the pathological features and establish a therapeutic approach of this disease, an animal model carrying the phenotype of Graves' disease (GD) in concert with Graves' Ophthalmopathy (GO) will be very important. However, there are no ideal animal models that are currently available. Read More

    Measuring TSH receptor antibody to influence treatment choices in Graves' disease.
    Clin Endocrinol (Oxf) 2017 May;86(5):652-657
    Department of Diabetes and Endocrinology, Aberdeen Royal Infirmary, Aberdeen, UK.
    TSH receptor antibody (TRAb) plays a key role in the pathogenesis of Graves' disease (GD), and its levels correlate with the clinical course. The second- and third-generation TRAb assays have >95% sensitivity and specificity for the diagnosis of GD and have improved the utility of TRAb to predict relapse. TRAb levels decline with antithyroid drug (ATD) therapy and after thyroidectomy. Read More

    Mechanism of MicroRNA-146a/Notch2 Signaling Regulating IL-6 in Graves Ophthalmopathy.
    Cell Physiol Biochem 2017 8;41(4):1285-1297. Epub 2017 Mar 8.
    Department of Gastric Cancer Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
    Background/aims: We intended to investigate the significance of microRNA-146a, Notch2 and IL-6 on Graves ophthalmopathy (GO) and the relationships among them.

    Methods: About 27 GO patients were incorporated in this study, including 13 patients with inactive GO and14 patients with active GO. Another 15 patients who had previously received strabismus orthopedics or ophthalmectomy due to trauma were selected as the control population. Read More

    [Multi-wall orbital decompression for disfiguring proptosis in patients with mild or moderate thyroid eye disease].
    Zhonghua Yan Ke Za Zhi 2017 Feb;53(2):128-135
    Institute of orbital diseases, the General Hospital of the Armed Police Force, Beijing100039, China.
    Objective: To evaluate the efficacy of orbital decompression by transconjunctival medial and inferior wall combined transpalpebral lateral wall for disfiguring proptosis with mild or moderate thyroid eye disease (TED). Methods: It is a retrospective case series study. The clinical data of 18 TED cases (28 orbits) between Dec 2013 and Dec 2015 at the Institute of Orbital Diseases of the General Hospital of the Armed Police were reviewed. Read More

    Mortality in Graves' orbitopathy is increased and influenced by gender, age and pre-existing morbidity: a nationwide Danish register study.
    Eur J Endocrinol 2017 Jun 3;176(6):669-676. Epub 2017 Mar 3.
    Department of Endocrinology and MetabolismOdense University Hospital, Odense, Denmark.
    Introduction: It is unclear whether the excess mortality associated with Graves' disease differs between individuals with Graves' orbitopathy (GO) or without (GD).

    Subjects And Methods: A nationwide, register-based cohort study in which all adult Danes diagnosed with GD (n = 28 461) and GO (n = 3965) between 1995 and 2012 were matched for age and gender with four control subjects. Median follow-up time was 7. Read More

    The role of rectus muscle myectomy in the management of large-angle strabismus for Graves' ophthalmopathy.
    Eye (Lond) 2017 Mar 3. Epub 2017 Mar 3.
    Department of Ophthalmology, Mackay Memorial Hospital, Taipei, Taiwan.
    PurposeRetrospective noncomparative case series to investigate the role of rectus muscle myectomy for the treatment of large-angle strabismus in patients with Graves' ophthalmopathy.Patients and methodsData from 47 consecutive patients with Graves' ophthalmopathy who underwent complete myectomy for large-angle strabismus (strabismus greater than 25 prism diopters (PDs)) were collected retrospectively. Pre- and postoperative deviations in primary and reading position were measured in PDs. Read More

    Orbital Decompression for Thyroid Eye Disease.
    Semin Plast Surg 2017 Feb;31(1):40-45
    Division of Ophthalmology, Baylor College of Medicine, Houston, Texas.
    Although most cases of thyroid eye disease (TED) can be managed medically, some refractory or severe cases are treated surgically with orbital decompression. Due to a lack of randomized controlled trials comparing surgical techniques for orbital decompression, none have been deemed superior. Thus, each case of TED is managed based on patient characteristics and surgeon experience. Read More

    Subconjunctival orbital fat prolapse and thyroid associated orbitopathy: a clinical association.
    Clin Interv Aging 2017 13;12:359-366. Epub 2017 Feb 13.
    Athens General Hospital "G. Gennimatas", Athens, Greece.
    Background: Thyroid associated orbitopathy (TAO) comprises a spectrum of well-recognized clinical signs including exophthalmos, eyelid retraction, soft tissue swelling, ocular misalignment, keratopathy as well as a number of less common manifestations. Subconjunctival fat prolapse is a rare clinical condition occurring typically spontaneously in elderly patients with a mean age of 65-72 years. We describe subconjunctival prolapse of orbital fat as an uncommon clinical association of TAO. Read More

    Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves' disease.
    Arch Endocrinol Metab 2017 Feb 16. Epub 2017 Feb 16.
    División Endocrinología, Hospital de Agudos J. M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina.
    Objective: The aim of this study was to measure quality of life (QOL) impairment in individuals currently suffering from Graves' ophthalmopathy (GO) and to determine the correlation of GO-specific QOL scores with disease severity and activity.

    Subjects And Methods: Seventy three GO-specific QOL surveys were prospectively analysed and compared with GO status. The GO-specific QOL survey was translated into Spanish and applied to Argentine patients with Graves' disease (GD). Read More

    Decreased Frequencies of Peripheral Blood CD4+CD25+CD127-Foxp3+ in Patients with Graves' Disease and Graves' Orbitopathy: Enhancing Effect of Insulin Growth Factor-1 on Treg Cells.
    Horm Metab Res 2017 Mar 21;49(3):185-191. Epub 2017 Feb 21.
    Department of Nuclear Medicine, Medical University of Bialystok, Bialystok, Bialystok, Poland.
    Graves' orbitopathy (GO) is characterized by orbital T cell infiltration. We evaluated the regulatory T (Treg) cell fractions induced with IGF-1 in Graves' disease (GD) with and without GO. Peripheral blood mononuclear cells (PBMCs) were obtained from 13 patients with GD without eye manifestations; 10 patients with active GO; and 12 patients with nodular goiter (NG). Read More


    Treatment by rituximab on six Grave's ophthalmopathies resistant to corticosteroids.
    Ann Endocrinol (Paris) 2017 Feb 6;78(1):20-26. Epub 2017 Feb 6.
    Service d'ophtalmologie, hôpital Bretonneau, centre hospitalier universitaire de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France; Faculté de médecine de Tours, 10, boulevard Tonnellé, BP 3223, 37032 Tours cedex 1, France.
    Objectives: Graves' ophthalmopathy occurs in 50% of Graves' disease cases. Treatment is based on smoking cessation, and control of the euthyroidism and ocular repercussions associated with the disease. The active orbital forms are treated with glucocorticoids. Read More

    The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.
    Drugs 2017 Mar;77(3):303-311
    York Teaching Hospitals NHS Foundation Trust, Wigginton Road, York, Yo31 8HE, UK.
    Recent times have seen an increase in the number of options to treat multiple sclerosis. Ocular manifestations of multiple sclerosis are well known to treating physicians; however, the medications used to treat multiple sclerosis can also have ocular side effects. This review article focuses on the ocular manifestations of corticosteroids and disease-modifying agents such as interferon, fingolomod, natalizumab, alemtuzumab and mitoxantron used to treat the disease. Read More

    Changing trend in referral to secondary care specialist thyroid eye disease clinic following the Amsterdam declaration.
    Int Ophthalmol 2017 Feb 8. Epub 2017 Feb 8.
    Department of Endocrinology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK.
    Introduction: Early diagnosis and treatment of thyroid eye disease (TED) improves outcomes. Previous studies have highlighted delays in diagnosis and referral to specialist centres. The Amsterdam declaration (2009) aimed to halve the time from presentation to diagnosis and from diagnosis to referral to a specialist centre in five years. Read More

    Poly (ADP-Ribose) Polymerase-1 (PARP-1) in Chinese patients with Graves Disease and Graves Ophthalmopathy.
    Can J Physiol Pharmacol 2017 Jan 29. Epub 2017 Jan 29.
    Tianjin First Center Hospital ,Tianjin , Tianjin , China ;
    We aimed to evaluate the genetic variation of poly (ADP-ribose) polymerase-1 (PARP-1) as risk factor in development of Graves' disease (GD) and Graves Ophthalmopathy (GO) among Chinese individuals. Patients with confirmed diagnosis of GD or healthy individuals with no clinical symptoms of hyperthyroiditis were enrolled at department of Ophthalmology, Tianjin First Center Hospital, China. Genetic polymorphism was studied in plasma DNA samples of subjects by polymererase chain reaction of restriction fragment length polymorphism to confirm test our hypothesis. Read More

    Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?
    J Endocrinol Invest 2017 May 7;40(5):547-553. Epub 2017 Feb 7.
    Gutenberg University Medical Center, Mainz, Germany.
    Purpose: Intravenous glucocorticoids (ivGCs) given as 12-weekly infusions are the first-line treatment for moderate-to-severe and active Graves' orbitopathy (GO), but they are not always effective. In this study, we evaluated whether response at 6 weeks correlated with outcomes at 12 (end of intervention) and 24 (follow-up) weeks, particularly in patients initially unresponsive.

    Methods: Our database (Bartalena et al. Read More

    [Epidemiological, clinical, therapeutic and evolutive aspects of Basedow-Graves disease in the Depatment of Internal Medicine at CHU Aristide Le Dantec, Dakar (Senegal)].
    Pan Afr Med J 2016 14;25. Epub 2016 Sep 14.
    Médecine Interne, Centre Hospitalier Universitaire Aristide Le Dantec, Dakar, Sénégal.
    Basedow-Graves disease is an autoimmune affection characterized by the association of thyrotoxicosis with variable frequency events such as goiter, ophthalmopathy and pretibial myxedema. Its diagnosis is often easy, while its management remains difficult. A simple medical treatment exposes patient to recurrence risk. Read More

    TSHR as a therapeutic target in Graves' disease.
    Expert Opin Ther Targets 2017 Apr 6;21(4):427-432. Epub 2017 Feb 6.
    a Department of Ophthalmology and Visual Sciences , University of Michigan , Ann Arbor , MI , USA.
    Introduction: Graves' disease (GD) and thyroid-associated ophthalmopathy (TAO) are thought to result from actions of pathogenic antibodies mediated through the thyrotropin receptor (TSHR). This leads to the unregulated consequences of the antibody-mediated receptor activity in the thyroid and connective tissues of the orbit. Recent studies reveal antibodies that appear to be directed against the insulin-like growth factor-I receptor (IGF-IR). Read More

    Correlation of HLA-DQ and TNF-α gene polymorphisms with ocular myasthenia gravis combined with thyroid-associated ophthalmopathy.
    Biosci Rep 2017 Apr 27;37(2). Epub 2017 Mar 27.
    Department of Neurology, Affiliated Hospital of Medical College, Qingdao University, Qingdao 266000, P.R. China.
    The present study aims to explore the correlation of human leucocyte antigen (HLA)-DQ and tumour necrosis factor (TNF)-α gene polymorphisms with ocular myasthenia gravis (OMG) combined with thyroid-associated ophthalmopathy (TAO). From March 2009 to March 2015, 56 OMG patients complicated with TAO (OMG + TAO group), 134 patients diagnosed with OMG only (OMG group) and 236 healthy individuals (control group) were enrolled in the present study. PCR-sequence specific primer (PCR-SSP) was used for HLA-DQ genotyping and PCR-restriction fragment length polymorphism (PCR-RFLP) for TNF-α genotyping. Read More


    Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.
    Front Endocrinol (Lausanne) 2016 3;7:167. Epub 2017 Jan 3.
    Department of Internal Medicine, Erasmus Medical Center, Division of Endocrinology , Rotterdam , Netherlands.
    The pathogenesis of orbital Graves' disease (GD), a process known as thyroid-associated ophthalmopathy (TAO), remains incompletely understood. The thyrotropin receptor (TSHR) represents the central autoantigen involved in GD and has been proposed as the thyroid antigen shared with the orbit that could explain the infiltration of immune cells into tissues surrounding the eye. Another cell surface protein, insulin-like growth factor-I receptor (IGF-IR), has recently been proposed as a second antigen that participates in TAO by virtue of its interactions with anti-IGF-IR antibodies generated in GD, its apparent physical and functional complex formation with TSHR, and its necessary involvement in TSHR post-receptor signaling. Read More

    Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy.
    Curr Pharm Des 2017 ;23(4):639-654
    Jozef Strus Poznan City Hospital, Department of Ophthalmology, 3 Szwajcarska St, 361-285 Poznan. Poland.
    Background: Tobacco smoking has detrimental influence on human health.

    Aim: The analysis of influence of tobacco smoking on retina diseases, uveitis, optic neuropathies, and thyroidassociated orbitopathy in adults and children.

    Methods: A comprehensive review of the literature performed through MEDLINE and PubMed searches, covering the years 2000-2016. Read More

    Distinct inflammatory gene expression in extraocular muscle and fat from patients with Graves' orbitopathy.
    Eur J Endocrinol 2017 Apr 11;176(4):481-488. Epub 2017 Jan 11.
    Endocrinology UnitDepartment of Medicine
    Objective: This study sought to compare patients with thyroid eye disease (TED) and normal controls with respect to the expression of the NR3C1, CHUK, IKBKB, FOS, NFKB and HSD11B1 genes in orbital fat (OF) and extraocular muscle (EOM).

    Design And Methods: A prospective study design was used to evaluate 34 TED patients and 38 healthy controls. OF was harvested from 33 TED patients and 27 controls. Read More

    [Autoimmune diseases of the thyroid gland].
    Internist (Berl) 2017 Jan;58(1):47-58
    Funktionsbereich Spezielle Endokrinologie, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
    Autoimmune diseases of the thyroid gland are considered to be the most frequent cause of thyroid gland disorders. Autoimmune thyroid diseases consist of two subgroups: autoimmune thyroiditis (AIT) and Graves' disease. The AIT is the most common human autoimmune disease. Read More

    Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids?
    Ir J Med Sci 2017 Jan 3. Epub 2017 Jan 3.
    Department of Neuroscience, Odontostomatological and Reproductive Sciences, University "Federico II" of Naples, via Pansini no 5, 80131, Naples, Italy.
    Background And Aims: To evaluate the efficacy of orbital radiotherapy (OR) for the treatment of thyroid eye disease (TED).

    Methods: Thirty-five consecutive patients with active TED with contraindications to steroid therapy received a course of OR. Bilateral retrobulbar irradiation was performed with a total dose of 20 Gy. Read More

    The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients.
    Pharmacology 2017 4;99(3-4):144-152. Epub 2017 Jan 4.
    Department of Thyroid Breast Surgery, Yinzhou Hospital of Ningbo University Medical College, Ningbo, China.
    Purpose: The purpose of this study is to examine the effectiveness of introducing both rituximab (RTX) and 131I for active Graves' ophthalmopathy (GO) with hyperthyroidism.

    Methods: In total, 217 patients suffering from active GO with hyperthyroidism were included in this research. All subjects were randomly assigned to 3 groups. Read More

    1 OF 77